by
Gillian Tan, Layan Odeh
A new vehicle would follow the company's Starwood Distressed Opportunity Fund XII.
by
Bloomberg News
If Oaktree Opportunities Fund XII surpasses $18 billion, it would be the largest private debt fund of all time.
by
Edward Hayes
But mutual funds will remain a key part of retirement and separate account strategies, the firm said.
by
Dawn Lim
Key Blackstone funds swore off backing oil and gas exploration and production in 2022.
by
Tracey Longo
The timing of purchases and sales has caused investors to miss out on potential gains.
by
Ben Mattlin
The 60/40 model is still viable, but it's not a "one-size-fits-all" solution, strategist Todd Schlanger said.
by
Lu Wang
Regulations dating back over 80 years set limits on how concentrated a “diversified” mutual fund can be.
by
Karen DeMasters
American Century Investments is being the contrarian in the face of recent optimism, Victor Zhang said.
by
Edward Hayes
Equities trended downward last year in a turbulent market, according to a white paper by tech firm Advyzon.
by FA Staff
Many investors would shy away from investments in controversial weapons, As You Sow said.
by
Jeff Stimpson
The sharp rise in interest rates since March 2022 has created a surge in clients looking to deploy their cash.
by
Katie Greifeld
The David Booth-founded firm wants to create ETFs as a share class of its mutual funds.
by
Jeff Schlegel
Fund manager Chris Davis says the stocks of the largest, best-of-breed banks are primed for upside.
by
Alexandra Harris, Lydia Beyoud
The regulator's rules are meant to discourage runs and shield remaining shareholders from costs tied to redemptions.
by
Jessica Menton
Investors have yanked nearly $44 billion from funds that track growth shares since the start of the year.
by
Stephan Kahl
“There's not much alpha left in a traditional Treasury,” CEO Oliver Baete said.
by
Miles Weiss, Silla Brush
The fund primarily makes floating-rate loans to middle-market, private US companies.
by
John Sage
The Oaktree Life Sciences Lending Fund will lend directly to biopharmaceutical and medical device companies.
by
Silla Brush
The firm said in January that it would dismiss 500 employees, or roughly 2.5% of its global workforce.
